BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$82.96 USD
-8.24 (-9.04%)
Updated Apr 25, 2024 12:50 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Company Summary
San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mainly for children.
The company's portfolio comprises eight marketed products, namely, Aldurazyme (for mucopolysaccharidosis type I (MPS I)), Naglazyme (for MPS VI), Kuvan (for phenylketonuria (PKU) – a rare genetic enzyme deficiency disorder), Vimizim (for MPS IVA or Morquio syndrome type A), Brineura (for CLN2– a form of Batten disease), Palynziq (for PKU), Voxzogo (for achondroplasia) and Roctavian (for severe hemophilia A). BioMarin has a collaboration agreement with Sanofi’s subsidiary, ...
Company Summary
San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mainly for children.
The company's portfolio comprises eight marketed products, namely, Aldurazyme (for mucopolysaccharidosis type I (MPS I)), Naglazyme (for MPS VI), Kuvan (for phenylketonuria (PKU) – a rare genetic enzyme deficiency disorder), Vimizim (for MPS IVA or Morquio syndrome type A), Brineura (for CLN2– a form of Batten disease), Palynziq (for PKU), Voxzogo (for achondroplasia) and Roctavian (for severe hemophilia A). BioMarin has a collaboration agreement with Sanofi’s subsidiary, Genzyme, for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
Currently, management is developing two pipeline candidates, BMN 255 and BMN 331, targeting hyperoxaluria in chronic liver disease and hereditary angioedema (HAE) in separate phase I/II studies. In the next couple of years, BioMarin intends to start more preclinical candidates targeting cardiovascular and central nervous system indications for clinical development.
In February 2024, management announced that it had started a strategic portfolio review of all R&D programs to determine which pipeline programs should be selected and advanced for further development. A complete update on this review is expected at the company’s Investor’s Day event, which is scheduled to be held before 2024-end.
BioMarin generated total revenues of $2.4 billion in 2023, up 15% from a year ago.
General Information
BioMarin Pharmaceutical Inc
770 Lindaro Street
San Rafael, CA 94901
Phone: 415-506-6700
Fax: 415-382-7889
Web: http://www.bmrn.com
Email: ir@bmrn.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 7/29/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.63 |
Current Year EPS Consensus Estimate | 2.76 |
Estimated Long-Term EPS Growth Rate | 29.30 |
Exp Earnings Date | 7/29/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 91.20 |
52 Week High | 99.56 |
52 Week Low | 76.02 |
Beta | 0.31 |
20 Day Moving Average | 1,354,270.12 |
Target Price Consensus | 108.76 |
4 Week | 2.92 |
12 Week | 3.54 |
YTD | -5.41 |
4 Week | 6.51 |
12 Week | -1.07 |
YTD | -11.04 |
Shares Outstanding (millions) | 188.73 |
Market Capitalization (millions) | 17,212.52 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 33.00 |
Trailing 12 Months | 41.46 |
PEG Ratio | 1.13 |
vs. Previous Year | 136.36% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 20.22% |
vs. Previous Quarter | 11.16% |
Price/Book | 3.47 |
Price/Cash Flow | 50.98 |
Price / Sales | 6.96 |
3/31/24 | NA |
12/31/23 | 5.01 |
9/30/23 | 4.45 |
3/31/24 | NA |
12/31/23 | 3.64 |
9/30/23 | 3.23 |
3/31/24 | NA |
12/31/23 | 2.51 |
9/30/23 | 2.54 |
3/31/24 | NA |
12/31/23 | 1.57 |
9/30/23 | 1.65 |
3/31/24 | NA |
12/31/23 | 9.99 |
9/30/23 | 9.12 |
3/31/24 | NA |
12/31/23 | 6.93 |
9/30/23 | 6.36 |
3/31/24 | NA |
12/31/23 | 7.79 |
9/30/23 | 6.56 |
3/31/24 | NA |
12/31/23 | 26.29 |
9/30/23 | 26.00 |
3/31/24 | NA |
12/31/23 | 0.51 |
9/30/23 | 0.53 |
3/31/24 | NA |
12/31/23 | 0.12 |
9/30/23 | 0.12 |
3/31/24 | NA |
12/31/23 | 10.70 |
9/30/23 | 10.80 |